Effects of azilsartan for coagulatic and fiblinolytic markers in pathients with hypertension

Effects of azilsartan for coagulatic and fiblinolytic markers in pathients with hypertension - azilsartan and coagulatic and fiblinolytic markers

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012060

Enrollment

100

Registered

2013-10-17

Start date

2013-11-01

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

Medicine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: malignancy

Design outcomes

Primary

Measure	Time frame
therapeutic efficacy	—

Countries

Japan

Contacts

Public ContactShosaku Nomura

Kansai Medical University First Department of Internal Medicine

nomurash@hirakata.kmu.ac.jp072-804-2754

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026